Baseline characteristics

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL · Source last updated 2012-10-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      16

   units

   Participants

groups

1. description

   KW-0761 was administered 4 times at one-week intervals at a dose of 0.01, 0.1, 0.5 or 1.0 mg/kg in patients with CCR4 positive ATL or CCR4 positive PTCL

   id

   BG000

   title

   KW-0761

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            46

            upper Limit

            69

            value

            62

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            8

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            8

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            13

      title

      ATL

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            3

      title

      PTCL

   param Type

   NUMBER

   title

   Diagnosis

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice